Answers are grounded in this paper and cite their sources.
BACKGROUND: Antemortem definitive diagnosis of lymphoma in horses is often difficult. Thymidine kinase 1 (TK1) assay is a potentially useful biomarker for lymphoma in horses. HYPOTHESIS/OBJECTIVES: To report the clinical performance of a commercially available TK1 assay for diagnosis of lymphoma in horses. We hypothesized that there would be no association between serum TK1 activity and a diagnosis of lymphoma in horses. ANIMALS: Forty-two hospitalized horses, 14 with a definitive diagnosis of lymphoma, 4 with other neoplasia, and 24 with inflammatory disease. METHODS: Retrospective medical record review, groups were compared via Kruskal-Wallis and Mann-Whitney tests, and logistic regression was performed. RESULTS: Median (range) TK1 was 3 U/L (0.4-17.7 U/L) in horses with lymphoma and 3.9 U/L (0.8-94 U/L) in horses without lymphoma (P = .59). There was no significant difference in total protein between horses with and without lymphoma (6.6 g/dL [5.5-8.3 g/dL] vs 6.6 g/dL [4.7-10.4 g/dL]; P = .83). There was no significant difference in fibrinogen between horses with and without lymphoma (447 [100-1364] mg/dL vs 433 [291-2004] mg/dL; P = .47). On logistic regression, serum TK1 activity was not associated with a diagnosis of lymphoma (odds ratio, 0.97; 95% confidence interval, 0.9-1.05, P = .48). CONCLUSION AND CLINICAL IMPORTANCE: Serum TK1 values were not predictive of lymphoma diagnosis in this cohort of horses.
No takes yet. Share an insight, caveat, or question.
Moore et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: